A Phase 3 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 6 sites in 2 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2011-06-28.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 4th largest by enrollment, is one of 5 that started in 2009, is one of 10 in phase 3, and was the 9th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 612 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one is the 4th largest by enrollment, is one of 5 that started in 2009, is one of 9 in phase 3, and was the 9th registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, placebo and tamsulosin-controlled, parallel design, multinational study to evaluate the efficacy and safety of Tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign prostatic hyperplasia (BPH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Placebo
Drug: Tadalafil
Drug: Tadalafil
Drug: Tamsulosin
by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
Also known as: LY450190, Cialis
PO, QD (30 min after meal) for 12 weeks
PO, QD (30 min after meal) for 12 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks
The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.
Time frame: baseline, 12 weeks
Change From Baseline to 12 Weeks in International Prostate Symptom Score (IPSS) Subscore (Storage [Irritative] and Voiding [Obstructive])
IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms); 4 questions of the obstructive score range from 0 to 20. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); 3 questions of the irritative subscore range from 0 to 15. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.
Time frame: baseline, 12 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks
Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible). Least Squares Mean values were controlled for Benign Prostatic Hyperplasia severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.
Time frame: baseline, 12 weeks
Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks
The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least Squares Mean values were controlled for BPH severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.
Time frame: baseline, 12 weeks
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks
Qmax: defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using standard calibrated flowmeter). Least Squares Mean values were controlled for Benign Prostatic Hyperplasia (BPH) severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.
Time frame: baseline, 12 weeks
Patient Global Impression of Improvement (PGI-I) at Week 12
The PGI-I measures the patient's perception of improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).
Time frame: 12 weeks
Clinician Global Impression of Improvement (CGI-I) at Week 12
The CGI-I measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).
Time frame: 12 weeks
Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks
Nanograms of PSA per milliliter (ng/mL) of blood.
Time frame: baseline, 12 weeks
Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks
The PVR is defined as the volume of urine remaining in the bladder after voiding, estimated by ultrasound.
Time frame: baseline, 12 weeks
Change From Baseline in Blood Pressure (Sitting) at 12 Weeks
Time frame: baseline, 12 weeks
Change From Baseline in Blood Pressure (Standing) at 12 Weeks
Time frame: baseline, 12 weeks
Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks
Time frame: baseline, 12 weeks
| Milestone | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Started | 154 | 151 | 155 | 152 |
| Completed | 145 | 136 | 137 | 143 |
| Not completed | 9 | 15 | 18 | 9 |
| Withdrew: Adverse event | 1 | 5 | 7 | 2 |
| Withdrew: Entry criteria not met | 1 | 2 | 1 | 1 |
| Withdrew: Lack of efficacy | 3 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 2 | 2 | 4 | 1 |
| Withdrew: Withdrawal by subject | 1 | 5 | 5 | 2 |
The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.
| Units on a scale | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks | -3.0 ± 0.4 | -4.8 ± 0.4 | -4.7 ± 0.4 | -5.5 ± 0.4 |
IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms); 4 questions of the obstructive score range from 0 to 20. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); 3 questions of the irritative subscore range from 0 to 15. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.
| units on a scale | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Voiding (Obstructive) Score (N = 154,151,155,152) | -1.9 ± 0.3 | -3.3 ± 0.3 | -3.0 ± 0.3 | -3.8 ± 0.3 |
| Storage (Irritative) Score (N = 154,151,155,152) | -1.1 ± 0.2 | -1.5 ± 0.2 | -1.7 ± 0.2 | -1.7 ± 0.2 |
Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible). Least Squares Mean values were controlled for Benign Prostatic Hyperplasia severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.
| units on a scale | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks | -0.5 ± 0.1 | -0.8 ± 0.1 | -0.8 ± 0.1 | -1.1 ± 0.1 |
The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least Squares Mean values were controlled for BPH severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.
| units on a scale | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks | -0.8 ± 0.2 | -1.1 ± 0.2 | -1.0 ± 0.2 | -1.6 ± 0.2 |
Qmax: defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using standard calibrated flowmeter). Least Squares Mean values were controlled for Benign Prostatic Hyperplasia (BPH) severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.
| milliliter per second (mL/sec) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks | 2.1 ± 0.4 | 1.6 ± 0.4 | 1.3 ± 0.4 | 2.1 ± 0.4 |
The PGI-I measures the patient's perception of improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).
| Participants | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Very Much Worse | 2 | 1 | 1 | 0 |
| Much Worse | 3 | 1 | 0 | 1 |
| A Little Worse | 12 | 4 | 5 | 4 |
| No Change | 45 | 26 | 23 | 25 |
| A Little Better | 54 | 62 | 74 | 58 |
| Much Better | 32 | 44 | 40 | 53 |
| Very Much Better | 4 | 9 | 10 | 9 |
The CGI-I measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).
| participants | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Very Much Worse | 0 | 2 | 0 | 0 |
| Much Worse | 3 | 3 | 1 | 1 |
| A Little Worse | 8 | 4 | 3 | 3 |
| No Change | 44 | 21 | 29 | 19 |
| A Little Better | 60 | 67 | 62 | 68 |
| Much Better | 30 | 39 | 48 | 47 |
| Very Much Better | 7 | 11 | 10 | 12 |
Nanograms of PSA per milliliter (ng/mL) of blood.
| microgram/Liter | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks | -0.03 ± 0.55 | 0.04 ± 0.54 | 0.13 ± 0.59 | -0.06 ± 0.61 |
The PVR is defined as the volume of urine remaining in the bladder after voiding, estimated by ultrasound.
| milliliter (mL) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks | -1.20 ± 45.35 | -0.09 ± 45.21 | -2.90 ± 48.84 | -5.67 ± 34.38 |
| mm Hg | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Systolic Blood Pressure | 0.9 ± 10.9 | -2.3 ± 11.0 | -0.5 ± 12.4 | 0.2 ± 12.2 |
| Diastolic Blood Pressure | -0.3 ± 8.6 | -2.5 ± 7.8 | -1.4 ± 8.1 | -0.6 ± 7.9 |
| mm Hg | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Systolic Blood Pressure | 0.8 ± 11.8 | -2.9 ± 12.3 | 0.6 ± 11.6 | -0.9 ± 13.7 |
| Diastolic Blood Pressure | 0.4 ± 8.1 | -2.3 ± 8.0 | -1.7 ± 8.2 | -1.0 ± 8.8 |
| beats per minute (bpm) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks | -0.3 ± 8.9 | 0.7 ± 8.3 | 0.6 ± 8.3 | 0.6 ± 7.8 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/154 (0.6%) | 24/154 (15.6%) |
| 2.5 mg Tadalafil | — | 4/151 (2.6%) | 38/151 (25.2%) |
| 5.0 mg Tadalafil | — | 0/155 (0%) | 42/155 (27.1%) |
| 0.2 mg Tamsulosin | — | 0/152 (0%) | 35/152 (23%) |
| Event | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| InjuryInjury, poisoning and procedural complications | 0/154 | 1/151 | 0/155 | 0/152 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/154 | 1/151 | 0/155 | 0/152 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/154 | 1/151 | 0/155 | 0/152 |
| Hepatic cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/154 | 1/151 | 0/155 | 0/152 |
| HypertensionVascular disorders | 0/154 | 1/151 | 0/155 | 0/152 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/154 | 0/151 | 0/155 | 0/152 |
| Event | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin |
|---|---|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 0/154 | 3/151 | 6/155 | 0/152 |
| Back painMusculoskeletal and connective tissue disorders | 1/154 | 1/151 | 4/155 | 1/152 |
| NasopharyngitisInfections and infestations | 3/154 | 3/151 | 2/155 | 1/152 |
| DizzinessNervous system disorders | 0/154 | 3/151 | 0/155 | 2/152 |
| HeadacheNervous system disorders | 1/154 | 3/151 | 3/155 | 1/152 |
| Hepatic function abnormalHepatobiliary disorders | 3/154 | 0/151 | 0/155 | 1/152 |
| NauseaGastrointestinal disorders | 0/154 | 0/151 | 3/155 | 0/152 |
| DiarrhoeaGastrointestinal disorders | 0/154 | 2/151 | 2/155 | 1/152 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/154 | 2/151 | 0/155 | 1/152 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/154 | 2/151 | 0/155 | 0/152 |
| Age Continuous(years) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin | Total |
|---|---|---|---|---|---|
| Mean | 63.7 ± 8.1 | 63.7 ± 7.2 | 62.3 ± 8.0 | 62.6 ± 7.9 | 63.1 ± 7.8 |
| Sex: Female, Male(Participants) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 154 | 151 | 155 | 152 | 612 |
| Race/Ethnicity, Customized(participants) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin | Total |
|---|---|---|---|---|---|
| Asian | 154 | 151 | 155 | 152 | 612 |
| Region of Enrollment(participants) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin | Total |
|---|---|---|---|---|---|
| Taiwan | 24 | 23 | 21 | 22 | 90 |
| Japan | 86 | 84 | 87 | 85 | 342 |
| Korea, Republic of | 44 | 44 | 47 | 45 | 180 |
| Body Mass Index (BMI)(kilograms/square meters (kg/m^2)) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin | Total |
|---|---|---|---|---|---|
| Mean | 24.3 ± 2.9 | 23.9 ± 2.8 | 24.2 ± 2.8 | 24.4 ± 2.9 | 24.2 ± 2.8 |
| Current Tobacco Use(participants) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin | Total |
|---|---|---|---|---|---|
| Yes | 27 | 30 | 36 | 23 | 116 |
| No | 127 | 121 | 119 | 129 | 496 |
| Current Alcohol Use(participants) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin | Total |
|---|---|---|---|---|---|
| Yes | 78 | 81 | 84 | 83 | 326 |
| No | 76 | 70 | 71 | 69 | 286 |
| Benign Prostatic Hyperplasia (BPH) Severity(participants) | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 0.2 mg Tamsulosin | Total |
|---|---|---|---|---|---|
| Moderate (IPSS<20) | 102 | 102 | 102 | 102 | 408 |
| Severe (IPSS>=20) | 52 | 49 | 53 | 50 | 204 |
7 further baseline measures are reported on the registry.
The record gives a start of Mar 2009, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil